Moderna (MRNA)

Business Overview

Moderna is the loss-making case, where cash runway and probability-weighted pipeline value do the work that earnings cannot. FY2025 revenue was $1,944M and the GAAP net loss $(2,822)M. COVID vaccines (Spikevax and mNEXSPIKE) were still 93.1% of revenue ($1,810M), and 99.6% of the $1,818M of net product sales. Cash and investments were $8,135M at year-end 2025, including a $600M first draw on a $1.5B credit facility.

The 93.1% share mirrors the 92.9% of Vertex's revenue from cystic fibrosis drugs, but Moderna is losing money and its mRNA technology has not yet produced revenue beyond COVID. With no earnings, P/E means nothing. Equity value is a risk-adjusted NPV (rNPV) on disclosed programmes, each weighted by its odds of approval, at the model's 10.0% nominal rate, plus net cash.

How Runway Maths Work

Net loss is not cash burn. FY2025 operating cash flow was $(1,873)M, an average of ~$468M a quarter. Yet Q4 2025 operating cash flow was +$930M despite a $(826)M GAAP net loss. Use the cash flow statement for the denominator (see the runway guide).

Indicative runway is $8.1B ÷ ~$0.47B a quarter ≈ 17.3 quarters, a little over four years. Management guided to December 2026 cash of $5.5-6.0B (excluding further credit-facility draws), implying ~$2.1-2.6B of cash use in 2026, faster than the FY2025 average. Carry both in the model, and treat neither as a fixed survival date.

On 1 September 2026 Moderna completed a $3.0B offering of 0% convertible senior notes due 2032 (8-K, 1 September 2026). That adds cash against the same quarterly outflow, and a debt to repay or convert into shares later.

Pipeline and rNPV

R&D was $3,132M in FY2025. The lead programme is intismeran autogene, an individualised mRNA cancer vaccine developed with Merck and given after melanoma surgery. It was fully enrolled in Phase 3 at the FY2025 results. On 19 August 2026 Merck and Moderna announced that the Phase 3 trial, INTerpath-001, met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival; the companies plan to discuss filings with regulators. In rNPV terms the programme has passed the Phase 3 step, so its remaining risk is filing and approval. In five-year Phase 2b data, intismeran added to Merck's immunotherapy KEYTRUDA cut the risk of recurrence or death by 49% against KEYTRUDA alone (filed disclosure). Analyst peak-sales estimates for melanoma ($500M-1.3B) are assumptions only.

Equity is rNPV plus net cash minus debt. Phase-transition odds from the phase success guide weight the cash flows: 7.9% from Phase I to approval across all indications in a BIO study of 2011-2020, or 6.7% on the later Citeline 2014-2023 data. Each new programme has to show the mRNA technology works again; the COVID vaccine alone does not earn later programmes extra value.

Valuation Framework

COVID revenue is shrinking, so the value rests on rNPV for intismeran and other disclosed programmes, plus $8.1B of liquidity, less the cash burned before new products earn.

For scale, the runway guide's fictional company has ~13.3 quarters ($2.0B of cash, $150M a quarter of burn), and Processa Pharma, a small clinical-stage company that disclosed going-concern doubt, had ~0.5 quarters at its Q1 2026 burn. The December 2026 cash guidance ($5.5-6.0B) is the forward check on Moderna's ~17 quarters.

What to Watch in the Financials

Operating burn. Reconcile it to quarterly operating cash flow. Quarters swing (Q4 2025 was +$930M), so use the trailing four.

COVID share (93.1%). $1,810M of $1,944M total revenue. Any value from the mRNA technology belongs in rNPV.

Intismeran filings and approval. The Phase 3 trial met its primary endpoint in August 2026, so the next swing in pipeline value is the regulatory decision. Peak-sales inputs are estimates only.

Key Risks

Burn against a smaller revenue base. With ~$468M a quarter of average burn on $1,944M of revenue, liquidity matters more than margins. Faster burn or slower pipeline progress shortens runway below the ~17 quarters indicated.

COVID fade. Revenue is concentrated in a declining product, and replacement revenue has to arrive before the cash guidance runs down.

Clinical attrition on intismeran. Model the programme with explicit phase probabilities and clearly labelled peak-sales estimates.

Overstating the technology. A 2025 paper in the Proceedings of the National Academy of Sciences argues platform value exists only once the technology is reused. The fall in COVID revenue is the counterexample.